# US 2017/0283807 A1 · Compositions and methods for diagnosis and treatment of prostate cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0283807 A1
- Document ID: US20170283807A1
- Status: Published application
- Kind: A1
- Application number: 15/532,087
- Filed: 2015-12-01
- Published: 2017-10-05
- Earliest claimed: 2014-12-01
- Assignees: Novartis AG
- Inventors: Zineb MOUNIR; Raymond PAL PAGLIARINI
- Web page: https://patentgrep.com/patent/US20170283807A1

## CPC

- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 47/6807: {the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense}
- A61P 35/00: Antineoplastic agents
- A61K 2039/5158: {Antigen-pulsed cells, e.g. T-cells}
- C12N 2310/10: Type of nucleic acid
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2320/10: in screening processes
- C12N 2320/31: Combination therapy
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides novel personalized therapies, kits, transmittable forms of information and methods for use in treating subjects having TMPRSS2:ERG positive prostate cancer, which we show is amenable to therapeutic treatment with a PRMT5 inhibitor. Kits, methods of screening for candidate PRMT5 inhibitors, and associated methods of treatment are also provided.

## Claims

### Claim 1

A method for inhibiting the proliferation of TMPRSS2:ERG positive prostate cancer cells in a subject in need thereof, the method comprising the step of administering to the subject a PRMT5 inhibitor in an amount that is effective to inhibit the proliferation of the TMPRSS2:ERG positive prostate cancer cells.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the PRMT5 inhibitor is selected from the group consisting of: a RNAi agent, a CRISPR, a TALEN, a zinc finger nuclease, an mRNA, an antibody or derivative thereof, an antibody-drug conjugate, a chimeric antigen receptor T cell (CART) or a low molecular weight compound.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the PRMT5 inhibitor is a low molecular weight compound.

### Claim 4 (depends on 2)

The method according to claim 2, wherein the PRMT5 inhibitor is a RNAi agent.

### Claim 5 (depends on 2)

The method according to claim 2, wherein the PRMT5 inhibitor is an antibody or derivative thereof.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the method further comprises the step of administering to a subject a second therapeutic agent.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the second therapeutic agent is an anti-cancer agent, anti-allergic agent, anti-nausea agent or anti-emetic agent, pain reliever, cytoprotective agent.

### Claim 8 (depends on 6)

The method according to claim 6, wherein the second therapeutic agent is an anti-cancer agent selected from the list consisting of: an Androgen Receptor antagonist, abiraterone, enzalutamide, bicalutamide, flutamide, HDAC inhibitor, fluorouracil (5-FU) irinotecan, a HDM2 inhibitor, a purine analogue, 6-thioguanine, 6-mercaptopurine, a CDK4 inhibitor, and LEE011 and inhibitors of HDM2i, PI3K/mTOR-I, MAPKi, RTKi, EGFRi, FGFRi, METi, IGFiRi, JAKi, and WNTi.

### Claim 9

A method of determining if a subject afflicted with prostate cancer will respond to therapeutic treatment with a PRMT5 inhibitor, comprising the steps of:
(a) evaluating a test sample obtained from said subject for TMPRSS2:ERG positivity, wherein TMPRSS2:ERG positivity indicates that the subject will respond to therapeutic treatment with a PRMT5 inhibitor;
wherein the method comprises any one or more of the following optional steps:
(b) determining the level and/or activity of PRMT5 in the subject, wherein steps a) and b) can be performed in any order;
(c) administering a therapeutically effective amount of a PRMT5 inhibitor to the subject; and
(d) determining the level and/or activity of PRMT5 in the subject following step c), wherein a decrease in the level and/or activity of PRMT5 is correlated with the inhibition of the proliferation of the cancer, and wherein steps c) and d) are performed after steps a) and b).

### Claim 10 (depends on 9)

The method according to claim 9, wherein the PRMT5 inhibitor is selected from the group consisting of: a RNAi agent, a CRISPR, a TALEN, a zinc finger nuclease, an mRNA, an antibody or derivative thereof, an antibody-drug conjugate, a chimeric antigen receptor T cell (CART) or a low molecular weight compound.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the PRMT5 inhibitor is a low molecular weight compound.

### Claim 12 (depends on 10)

The method according to claim 10, wherein the PRMT5 inhibitor is a RNAi agent.

### Claim 13 (depends on 10)

The method according to claim 10, wherein the PRMT5 inhibitor is an antibody or derivative thereof.

### Claim 14 (depends on 9)

The method according to claim 9, wherein the method further comprises the step of administering to a subject a second therapeutic agent.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the second therapeutic agent is an anti-cancer agent, anti-allergic agent, anti-nausea agent or anti-emetic agent, pain reliever, cytoprotective agent.

### Claim 16 (depends on 14)

The method according to claim 14, wherein the second therapeutic agent is an anti-cancer agent selected from the list consisting of: an Androgen Receptor antagonist, abiraterone, enzalutamide, bicalutamide, flutamide, HDAC inhibitor, fluorouracil (5-FU) irinotecan, a HDM2 inhibitor, a purine analogue, 6-thioguanine, 6-mercaptopurine, a CDK4 inhibitor, and LEE011, and inhibitors of HDM2i, PI3K/mTOR-I, MAPKi, RTKi, EGFRi, FGFRi, METi, IGFiRi, JAKi, and WNTi.

### Claim 17

A method of determining if a subject afflicted with prostate cancer will respond to therapeutic treatment with a PRMT5 inhibitor, comprising the steps of:
(a) evaluating a test sample obtained from said subject for methylation of R761 of Androgen Receptor, wherein methylation of R761 of Androgen Receptor indicates that the subject will respond to therapeutic treatment with a PRMT5 inhibitor;
wherein the method comprises any one or more of the following optional steps:
(b) determining the level and/or activity of PRMT5 in the subject, wherein steps a) and b) can be performed in any order;
(c) administering a therapeutically effective amount of a PRMT5 inhibitor to the subject; and
(d) determining the level and/or activity of PRMT5 in the subject following step c), wherein a decrease in the level and/or activity of PRMT5 is correlated with the inhibition of the proliferation of the cancer, and wherein steps c) and d) are performed after steps a) and b).

### Claim 18 (depends on 17)

The method according to claim 17, wherein the PRMT5 inhibitor is selected from the group consisting of: a RNAi agent, a CRISPR, a TALEN, a zinc finger nuclease, an mRNA, an antibody or derivative thereof, an antibody-drug conjugate, a chimeric antigen receptor T cell (CART) or a low molecular weight compound.

### Claim 19 (depends on 18)

The method according to claim 18, wherein the PRMT5 inhibitor is a low molecular weight compound.

### Claim 20 (depends on 18)

The method according to claim 18, wherein the PRMT5 inhibitor is a RNAi agent.

### Claim 21 (depends on 18)

The method according to claim 18, wherein the PRMT5 inhibitor is an antibody or derivative thereof.

### Claim 22 (depends on 17)

The method according to claim 17, wherein the method further comprises the step of administering to a subject a second therapeutic agent.

### Claim 23 (depends on 22)

The method according to claim 22, wherein the second therapeutic agent is an anti-cancer agent, anti-allergic agent, anti-nausea agent or anti-emetic agent, pain reliever, cytoprotective agent.

### Claim 24 (depends on 22)

The method according to claim 22, wherein the second therapeutic agent is an anti-cancer agent selected from the list consisting of: an Androgen Receptor antagonist, abiraterone, enzalutamide, bicalutamide, flutamide, HDAC inhibitor, fluorouracil (5-FU) irinotecan, a HDM2 inhibitor, a purine analogue, 6-thioguanine, 6-mercaptopurine, a CDK4 inhibitor, and LEE011, and inhibitors of HDM2i, PI3K/mTOR-I, MAPKi, RTKi, EGFRi, FGFRi, METi, IGFiRi, JAKi, and WNTi.

### Claim at position 25

-45. (canceled)

### Claim 46 (depends on 2)

The method according to claim 2, wherein the PRMT5 inhibitor is a CRISPR comprising a PRMT5-targeting domain comprising any one of SEQ ID NOs: 105-1477.

### Claim 47

(canceled)

### Claim 48 (depends on 10)

The method according to claim 10, wherein the PRMT5 inhibitor is a CRISPR comprising a PRMT5-targeting domain comprising any one of SEQ ID NOs: 105-1477.

### Claim 49 (depends on 18)

The method according to claim 18, wherein the PRMT5 inhibitor is a CRISPR comprising a PRMT5-targeting domain comprising any one of SEQ ID NOs: 105-1477.

### Claim 50 (depends on 17)

The method according to claim 17, wherein step (a) of the method comprises evaluating a test sample obtained from said subject for monomethylation of R761 of Androgen Receptor, wherein monomethylation of R761 of Androgen Receptor indicates that the subject will respond to therapeutic treatment with a PRMT5 inhibitor.

### Claim 51 (depends on 17)

The method according to claim 17, wherein step (a) of the method comprises evaluating a test sample obtained from said subject for dimethylation of R761 of Androgen Receptor, wherein dimethylation of R761 of Androgen Receptor indicates that the subject will respond to therapeutic treatment with a PRMT5 inhibitor.
